# Study of Trilaciclib and Lurbinectidin

Source: https://onco.cc/trials/nct05578326/  
OnCo record `nct05578326` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trilaciclib and lurbinectedin in lung cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.

## Summary

Study of Trilaciclib and Lurbinectidin is a phase 2, interventional study registered as NCT05578326 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 30 participants, started 2022-10-12 and due to reach its primary completion in 2026-12-25. Interventions recorded: Trilaciclib; Lurbinectedin. Conditions listed: Lung Cancer; Small-cell Lung Cancer. Primary outcome: The proportion of grade 4 neutropenia; The duration of grade 4 neutropenia. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05578326
- Phase: 2
- Setting: Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer
- Sponsor: UNC Lineberger Comprehensive Cancer Center
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05578326: https://clinicaltrials.gov/study/NCT05578326

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/), [Trilaciclib](https://onco.cc/drugs/trilaciclib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05578326.json